TRANSPLANTATION FOR MANTLE CELL LYMPHOMA: IS IT THE RIGHT TREATMENT OPTION FOR PATIENTS? CASE REPORT

Svetlana Krstevska Balkanov; Simona Stojanovska; Dragica Nikolova; Aleksandra Pivkova Veljanovska; Sanja Trajkova; Irina Panovska Stavridis; Bozidar Kocoski; Nevenka Ridova

Svetlana Krstevska Balkanov University Clinic of Hematology Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
Simona Stojanovska University Clinic of Hematology Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
Dragica Nikolova University Clinic of Hematology Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
Aleksandra Pivkova Veljanovska University Clinic of Hematology Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
Sanja Trajkova University Clinic of Hematology Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
Irina Panovska Stavridis University Clinic of Hematology Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
Bozidar Kocoski University Clinic of Hematology Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia
Nevenka Ridova University Clinic of Hematology Skopje, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, North Macedonia

Abstract

Mantle cell lymphoma is clinically and biologically heterogeneous disease, ranging from the indolent non-nodal leukemic variant to the highly malignant blastoid variant. Despite many recent therapeutic advances, mantle cell lymphoma (MCL) remains a largely incurable disease. The median age at diagnosis of MCL is 60–65 years. MCL usually presents with advanced extra nodal, bone marrow, peripheral blood, spleen, and gastrointestinal involvement. First-line treatment consists of chemoimmunotherapy, which may result in prolonged remission, but relapse should be expected. Sustained long-term remissions are achievable following autologous stem cell transplantation. In this case report, we present a case of MCL in 60-year-old men diagnosed initially presented with an abdominal tumor. The patient underwent autologous stem cell transplantation after achieving first remission.

Keywords: MCL, autologous stem cell transplantation, Bruton tyrosine kinase (BTK) inhibitors.

References

1. Dreyling M, Doorduijn J, Giné E, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403(10441):2293–2306.
2. Tolksdorf G, Stein H, Lennert K. Morphological and immunological definition of a malignant lymphoma derived from germinal-centre cells with cleaved nuclei (centrocytes). Br J Cancer. 1980;41:168–82.
3. Anita Kumar et al. New Directions for Mantle Cell Lymphoma in 2022. Am Soc Clin Oncol Educ Book 42, 614-628(2022). DOI:10.1200/EDBK_349509
4. Jain P, Wang ML. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022 May;97(5):638-656. doi: 10.1002/ajh.26523. PMID: 35266562
5. Thomas, C.J.; Carvajal, V.; Barta, S.K. Targeted Therapies in the Treatment of Mantle Cell Lymphoma. Cancers 2024, 16, 1937. https://doi.org/10.3390/cancers16101937
6. Fakhri B, Kahl B. Current and emerging treatment options for mantle cell lymphoma. Ther Adv Hematol. 2017 Aug;8(8):223-234. doi: 10.1177/2040620717719616.
7. Zhou Y, Chen H, Tao Y, Zhong Q, Shi Y. Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis. J Cancer 2021; 12(2):553-561. doi:10.7150/jca.51959. https://www.jcancer.org/v12p0553.htm.
8. Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. Am J Hematol. 2019; 94: 710–725. https://doi.org/10.1002/ajh.25487.